| Drug ID: | Drug80 |
|---|---|
| Drug Name: | Curcumin |
| CID: | 969516 |
| DrugBank ID: | DB11672 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NO |
| Other Approved: | NO |
| Identifier: | NCT00889161, , NCT04713631 |
| Molecular Formula: | C21H20O6 |
| Molecular Weight: | 368.4 g/mol |
| Isomeric SMILES: | COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O |
| Synonyms: | curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Gelbwurz; Haldar; Curcumin I; Souchet |
| Phase 0: | 11 |
| Phase 1: | 38 |
| Phase 2: | 67 |
| Phase 3: | 23 |
| Phase 4: | 14 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt675 | 969516 | Curcumin | 4843 | NOS2 | Homo sapiens (human) | None | |
| dt676 | 969516 | Curcumin | 765 | CA6 | Homo sapiens (human) | None | |
| dt677 | 969516 | Curcumin | 1576 | CYP3A4 | Homo sapiens (human) | None | |
| dt678 | 969516 | Curcumin | 4318 | MMP9 | Homo sapiens (human) | None | |
| dt679 | 969516 | Curcumin | 1789 | DNMT3B | Homo sapiens (human) | None | |
| dt680 | 969516 | Curcumin | 1786 | DNMT1 | Homo sapiens (human) | None | |
| dt681 | 969516 | Curcumin | 351 | APP | Homo sapiens (human) | None | |
| dt682 | 969516 | Curcumin | 759 | CA1 | Homo sapiens (human) | None | |
| dt683 | 969516 | Curcumin | 5743 | PTGS2 | Homo sapiens (human) | None | |
| dt684 | 969516 | Curcumin | 5594 | MAPK1 | Rattus norvegicus (Norway rat) | 11981161 | Curcumin inhibits the reaction [tetracaine results in increased phosphorylation of MAPK1 protein] |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02683759 | Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative Colitis | PHASE3 | UNKNOWN | Asian Institute of Gastroenterology, India | Ulcerative Colitis | DIETARY_SUPPLEMENT: Bio-enhanced Curcumin Soft Ge… | Details |
| NCT02683733 | Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis | PHASE3 | UNKNOWN | Asian Institute of Gastroenterology, India | Ulcerative Colitis | DIETARY_SUPPLEMENT: Bio-enhanced Curcumin Soft Ge… | Details |
| NCT01320436 | Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis | PHASE3 | COMPLETED | Sheba Medical Center | Ulcerative Colitis | DIETARY_SUPPLEMENT: Curcumin|DRUG: 5-aminosalicyl… | Details |
| NCT03122613 | Curcumin for Prevention of Relapse in Patients With Ulcerative Colitis | None | TERMINATED | Chinese University of Hong Kong | Ulcerative Colitis in Remission | DIETARY_SUPPLEMENT: Curcumin|DRUG: Placebo | Details |
| NCT04713631 | Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease | PHASE2 | RECRUITING | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Crohn's Disease | DRUG: Artesunate|DRUG: Curcumin|DRUG: Placebo A|D… | Details |
| NCT06867939 | A Pilot Study of Curcumin (Soloways in Patients With Inflammatory Bowel Disease Homozygous for the IL-10 Variant | Not Available | Not recruiting | S.LAB (SOLOWAYS) | Inflamatory Bowel Disease | Dietary Supplement: liposomal curcumin;Dietary Su… | Details |
| RBR-89q4ydz | Effect of supplementation with Curcuma Longa (extract) and Piperine on inflammatory markers, oxidative stress and glycoxidation in patients with Inflammatory Bowel Disease treated at a Teaching Hospital in Alagoa | Not Available | Not Recruiting | Universidade Federal de Alagoas | Inflammatory Bowel Disease | This is a double-blind randomized clinical trial.… | Details |
| NCT04879810 | Pilot Clinical Trial Investigating the Ability of Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease (IBD) | Not Available | Not recruiting | University of Louisville | Irritable Bowel Disease | Procedure: Sigmoidoscopy and biopsy, blood work | Details |
| JPRN-UMIN000015770 | Randomized double-blind multicenter study for anti-inflammatory effects of highly bioavailable curcumin on Crohn's disease. - Exploratory study for effects of highly bioavailable curcumin on Crohn's disease. | Not Available | Not Recruiting | Hamamatsu South Hospital, Centre for Gastroenterology and Inflammatory Bowel Disease Research | Crohn's disease (180 <= CDAI < 450) … | Standard therapy for Crohn's disease (Pentasa… | Details |
| NCT00889161 | Curcumin in Pediatric Inflammatory Bowel Disease | PHASE1 | COMPLETED | Seattle Children's Hospital | Inflammatory Bowel Disease|Ulcerative Colitis|Cro… | DRUG: Curcumin | Details |
| NCT05761327 | Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis | None | COMPLETED | Ardahan University | Ulcerative Colitis | OTHER: Mediterranean Diet|DIETARY_SUPPLEMENT: Cur… | Details |
| NCT02277223 | Curcumin in Pediatric Ulcerative Colitis | PHASE3 | WITHDRAWN | Schneider Children's Medical Center, Israel | Ulcerative Colitis | DIETARY_SUPPLEMENT: Curcumin|DRUG: Placebo | Details |
| NCT03500653 | Curcumin Supplementation as an Add on Treatment for Patients With Inflammatory Bowel Diseases Treated With Vedolizumab | None | UNKNOWN | Henit Yanai | Inflammatory Bowel Diseases | DIETARY_SUPPLEMENT: Curcumin|DIETARY_SUPPLEMENT: … | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S05 | Angiogenesis | cell proliferation; vascular permeability | ozanimod | The bioactive lipid S1P has been shown to activate NF-κB an… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Safety and efficacy of curcumin in the treatment of ulcerative colitis: An upda…
PMID: 39612780
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Treatment of Inflammatory Bowel Disease by Using Curcumin-Containing Self-Micro…
PMID: 39598530
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Background: The lack of local availability for drugs in the colon can be addressed by preparing a self-microemulsifying drug delivery system (SMEDDS)…
The efficacy of curcumin/Qing Dai combination in children with active ulcerativ…
PMID: 39403348
Year: 2024
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Curcumin and Qing Dai (QD) are herbal extracts that recently showed efficacy in treating inflammatory bowel disease (IBD). Since 2016, a …
Effect of Curcumin Plus Piperine on Redox Imbalance, Fecal Calprotectin and Cyt…
PMID: 39065700
Year: 2024
Relationship Type:
Treatment
Score: 6.5
The development and course of inflammatory bowel disease (IBD) are significantly influenced by inflammation and oxidative stress. Antioxidant therapy…
Stable Dietary Ora-Curcumin Formulation Protects from Experimental Colitis and …
PMID: 38891089
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a chronic gut disorder that also elevates the risk of colorectal cancer (CRC). The global incidence and severity …
[Research progress on curcumin improving chronic low-grade inflammation and rel…
PMID: 38812161
Year: 2024
Relationship Type:
Association
Score: 6.5
Curcumin@Fe/Tannic Acid Complex Nanoparticles for Inflammatory Bowel Disease Tr…
PMID: 38559927
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a serious public health issue because of its chronic and incurable nature. Common IBD drugs have limited efficacy…
Use of curcumin and its nanopreparations in the treatment of inflammatory bowel…
PMID: 38314128
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a nonspecific inflammatory disease of the intestine that includes Crohn's disease and ulcerative colitis. Because…
Colon-Targeted Oral Delivery of Hydroxyethyl Starch-Curcumin Microcapsules Load…
PMID: 38111343
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Combination therapy through colon-targeted oral delivery of multiple drugs presents a promising approach for effectively treating ulcerative colitis …
Evaluation of curcumin nanoemulsion effect to prevent intestinal damage
PMID: 38092264
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Curcumin has gained great prominence for the prevention and treatment of inflammatory bowel disease. However, studies have reported the low bioavaila…
Curcumin alleviated dextran sulfate sodium-induced colitis by recovering memory…
PMID: 37901446
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Restoration of immune homeostasis by targeting the balance between memory T helper (mTh) cells and memory follicular T helper (mTfh) cell…
Oral delivery of pectin-chitosan hydrogels entrapping macrophage-targeted curcu…
PMID: 37839497
Year: 2023
Relationship Type:
Treatment
Score: 6.5
The oral delivery of anti-inflammatory drugs has been a promising strategy for enhancing the clinical efficacy of ulcerative colitis (UC) treatment s…
"Dual sensitive supramolecular curcumin nanoparticles" in "advanced yeast parti…
PMID: 37679849
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Ulcerative colitis (UC) faces some barriers in oral therapy, such as how to safely deliver drugs to the colon and accumulate in the colon lesions. He…
Chondroitin sulfate functionalized palmitic acid and cysteine cografted-quatern…
PMID: 37441137
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Curcumin (CUR) has a regulatory effect on the gut microbiota (GM), and its significant anti-inflammatory properties make it a research hotspot for in…
Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Ran…
PMID: 37302449
Year: 2024
Relationship Type:
Treatment
Score: 6.5
BACKGROUND & AIMS: We evaluated the efficacy of herbal combination of curcumin-QingDai (CurQD) in active ulcerative colitis (UC). METHODS: Part I was…
A Curcumin-Modified Coordination Polymers with ROS Scavenging and Macrophage Ph…
PMID: 37195012
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Overexpression of classically activated macrophages (M1) subtypes and assessed reactive oxygen species (ROS) levels are often observed in patients wi…
Real-world experience with Curcumin-QingDai combination for patients with activ…
PMID: 37157131
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Curcumin and QingDai (QD, Indigo) have been shown to be effective for treating active ulcerative colitis (UC). AIM: To evaluate the real-…
Curcumin-QingDai Combination as Treatment for Moderate-Severe Ulcerative Colitis
PMID: 36824698
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Curcumin was shown in placebo-controlled trials to induce remission in mild-moderate ulcerative colitis (UC). QingDai (QD, Indigo), another herbal ex…
Curcumin-Based Nanomedicines in the Treatment of Inflammatory and Immunomodulat…
PMID: 36678859
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Curcumin (CUR) is a polyphenol extracted from the rhizome of Curcuma longa that possesses potent anti-inflammatory and antioxidant potential. Despite…
Folic acid-modified lactoferrin nanoparticles coated with a laminarin layer loa…
PMID: 36642354
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Curcumin (CUR) is a promising natural compound in ulcerative colitis (UC) treatment, but limited by its low oral bioavailability and poor targeting a…